

requirement that every electronic version of a medical Standard/Optional form be reviewed and granted an exception. The following fields must appear on the electronic version of the following form:

Item	Placement ¹
(Plotting Chart (Title)	Top of form.
(Standard Form 512 (Rev. 3/1994) (Form ID)	Bottom right corner of form.
Data Entry Fields	
Title of Purpose of Graph	
Data (Allow for at least 14 entries)	
Time (Allow for at least 14 entries)	
Graphic (Allow for at least 14 plots)	
Patient Information (Text)	Above below listed items.
Last Name	
First Name	
Middle Name	
Rank	
Rate	
Hospital or Medical Facility	
Register No.	
Ward No.	

FOR FURTHER INFORMATION CONTACT: Ms. Sheila P. Merriweather, Office of Minority Health, Rockwall Building, 5515 Security Lane, Suite 1000, Rockville, MD 20852. Phone: 301-443-9923, Fax: 301-443-8280.

Dated: March 4, 2002.

Nathan Stinson, Jr.,

Deputy Assistant Secretary for Minority Health.

[FR Doc. 02-5511 Filed 3-7-02; 8:45 am]

BILLING CODE 4150-29-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Prospective Grant of Exclusive License: Vaccines and Diagnostic Tests for Cat Scratch Fever

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intervet Inc. (Intervet) having a place of business in Millsboro, Delaware. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are:

Title: Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by *Rochalimaea henselae*.

U.S. Patent Application Serial No. 07/822,539.

Filing Date: 01/17/92.

Domestic Status: Patent No.:

5,399,485.

Issue Date: 03/21/95.

Title: Methods and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/245,294.

Filing Date: 05/18/94.

Domestic Status: Patent No.:

5,644,047.

Issue Date: 07/01/97.

Title: Nucleic acids specific for *Rochalimaea quintana*.

U.S. Patent Application Serial No. 08/474,499.

Filing Date: 06/07/95.

Domestic Status: Patent No.:

5,693,776.

Issue Date: 12/02/97.

Title: Nucleic acids of *Rochalimaea henselae* and methods and compositions

for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/307,279.

Filing Date: 09/16/94.

Domestic Status: Patent No.:

5,736,347.

Issue Date: 04/07/98.

Title: Composition to protect a mammal against *Bartonella henselae* infection.

U.S. Patent Application Serial No. 08/922,970.

Filing Date: 09/03/97.

Domestic Status: Patent No.:

5,958,414.

Issue Date: 09/28/99.

Title: Methods and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 08/472,904.

Filing Date: 06/07/95.

Title: Nucleic acids of *Rochalimaea henselae* and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/480,849.

Filing Date: 06/07/95.

Title: Methods and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 08/472,934.

Filing Date: 06/07/95.

Title: Nucleic Acids of *Rochalimaea Henselae* and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 09/525,310.

Filing Date: 03/14/00.

Title: Nucleic acids of *Rochalimaea henselae* and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 09/752,385.

Filing Date: 12/29/00.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Cat scratch fever or bacillary angiomatosis is a bacterial disease transmitted via a cat scratch or bite. A previously unidentified, pathogenic species of *Bartonella* (formerly *Rochalimaea*), *B. henselae*, has been identified as the primary causative agent. A related species, *B. quintana*, may also produce illness in immunocompromised individuals. This invention identifies immunogenic peptides useful for identification of *B. henselae* and diagnosis of bacillary angiomatosis and a method of vaccinating against bacillary angiomatosis.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: March 4, 2002.

Joseph R. Carter,

Associate Director for Management and Operations, Centers for Disease Control and Prevention.

[FR Doc. 02-5567 Filed 3-7-02; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Prospective Grant of Exclusive License: Growing *Ehrlichia* Species in a Continuous Cell Line

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (HHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intervet Inc. (Intervet) having a place of business in Millsboro, Delaware. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are: